MA20938A1 - Procede de preparation du besylate d'amlodipine. - Google Patents

Procede de preparation du besylate d'amlodipine.

Info

Publication number
MA20938A1
MA20938A1 MA21175A MA21175A MA20938A1 MA 20938 A1 MA20938 A1 MA 20938A1 MA 21175 A MA21175 A MA 21175A MA 21175 A MA21175 A MA 21175A MA 20938 A1 MA20938 A1 MA 20938A1
Authority
MA
Morocco
Prior art keywords
amlodipine besylate
preparing amlodipine
preparing
besylate
amlodipine
Prior art date
Application number
MA21175A
Other languages
English (en)
Inventor
Edward Davison
James Ingram Wells
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA20938(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MA20938A1 publication Critical patent/MA20938A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
MA21175A 1986-04-04 1987-04-03 Procede de preparation du besylate d'amlodipine. MA20938A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868608335A GB8608335D0 (en) 1986-04-04 1986-04-04 Pharmaceutically acceptable salts

Publications (1)

Publication Number Publication Date
MA20938A1 true MA20938A1 (fr) 1987-12-31

Family

ID=10595731

Family Applications (1)

Application Number Title Priority Date Filing Date
MA21175A MA20938A1 (fr) 1986-04-04 1987-04-03 Procede de preparation du besylate d'amlodipine.

Country Status (47)

Country Link
US (1) US4879303A (fr)
EP (1) EP0244944B1 (fr)
JP (1) JPS62240660A (fr)
KR (1) KR950006710B1 (fr)
CN (1) CN1023800C (fr)
AP (1) AP50A (fr)
AR (1) AR242562A1 (fr)
AT (1) ATE49752T1 (fr)
BE (1) BE1000130A4 (fr)
BG (1) BG60698B2 (fr)
CA (1) CA1321393C (fr)
CS (1) CS265237B2 (fr)
CY (1) CY1669A (fr)
CZ (1) CZ289095B6 (fr)
DD (1) DD265142A5 (fr)
DE (2) DE3710457A1 (fr)
DK (1) DK171708B1 (fr)
EC (1) ECSP941129A (fr)
EG (1) EG18266A (fr)
ES (2) ES2012803B3 (fr)
FI (1) FI85017C (fr)
FR (1) FR2596758B1 (fr)
GB (2) GB8608335D0 (fr)
GR (2) GR870525B (fr)
HK (1) HK76092A (fr)
HU (1) HU196962B (fr)
IE (1) IE59457B1 (fr)
IL (1) IL82101A (fr)
IN (1) IN168414B (fr)
IT (1) IT1203853B (fr)
LU (1) LU86812A1 (fr)
MA (1) MA20938A1 (fr)
MX (1) MX5847A (fr)
MY (1) MY101177A (fr)
NL (1) NL8700791A (fr)
NO (1) NO172181C (fr)
NZ (1) NZ219868A (fr)
PH (1) PH24348A (fr)
PL (1) PL149532B1 (fr)
PT (1) PT84611B (fr)
SE (1) SE463457B (fr)
SG (1) SG59692G (fr)
SK (1) SK278435B6 (fr)
SU (1) SU1498388A3 (fr)
UA (1) UA6344A1 (fr)
YU (1) YU44801B (fr)
ZA (1) ZA872439B (fr)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
WO1993010779A1 (fr) * 1991-11-26 1993-06-10 Sepracor, Inc. Procedes et compositions destines a traiter l'hypertension, l'angine de poitrine et d'autres troubles a l'aide de (-)amlodipine optiquement pure
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
AT399718B (de) * 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
US5389654A (en) * 1992-11-26 1995-02-14 Lek, Tovarna, Farmacevtskih In Kemicnih . . . 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate
SI9200344B (sl) * 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
EP0804229B1 (fr) 1995-03-16 2003-03-26 Pfizer Inc. Utlisation de l'amlodipine, un de ses sels ou de la felodipine en combinaison avec un inhibiteur de l'enzyme de conversion de l'angiotensine pour la fabrication d'un medicament destine au traitement de l'insuffisance cardiaque congestive non-ischemique
HU221810B1 (hu) * 1997-08-12 2003-01-28 EGIS Gyógyszergyár Rt. Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
WO1999018957A1 (fr) * 1998-03-26 1999-04-22 Reddy-Cheminor, Inc. Composition pharmaceutique stable contenant du besylate d'anilodipine et de l'atenolol
RU2188636C2 (ru) * 1998-03-26 2002-09-10 Др. Редди'С Лабораторис Лтд. Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол
PL189666B1 (pl) * 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
KR20040078140A (ko) 1998-07-10 2004-09-08 노파르티스 아게 발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
UA33033A (uk) * 1998-10-16 2001-02-15 Др.Редіс Леборетрис Лтд Спосіб одержання безилату амлодипіну
US7129265B2 (en) * 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
RU2142942C1 (ru) * 1999-04-28 1999-12-20 Дж. Б.Кемикалс энд Фармасьютикалс Лтд. Способ получения монобензолсульфоната 3-этил-5-метилового эфира 2-[(2-аминоэтокси)метил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5-пиридинди карбоновой кислоты
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
PL353483A1 (en) 1999-05-27 2003-11-17 Pfizer Products Inc. Mutual prodrugs of amlodipine and atorvastatin
RU2161156C1 (ru) * 1999-06-01 2000-12-27 Джи.Б.Кемикалс Энд Фармасьютикалс Лтд Способ получения 3-этил-5-метиловый эфир 2-[2-(n-фталимидо)-этоксиметил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5- пиридиндикарбоновой кислоты
UA72768C2 (en) * 1999-07-05 2005-04-15 Richter Gedeon Vegyeszet A method for obtaining amilodipine benzenesulphonate
RU2146672C1 (ru) * 1999-10-13 2000-03-20 Др.Редди'С Лабораторис Лтд. Способ получения 3-этил-5-метил(±)2[2-аминоэтокси)-метил]-4-(2-хлорфенил)-1,4-дигидро- 6-метил-3,5-пиридиндикарбоксилат монобензолсульфоната
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
AU2001283085A1 (en) 2000-08-04 2002-02-18 R. Preston Mason Synergistic effect of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
GB2372036B (en) * 2000-12-29 2004-05-19 Bioorg Bv Aspartate derivative of amlodipine
CA2433181C (fr) 2000-12-29 2005-11-22 Pfizer Limited Fumarate d'amlodipine
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
US6653481B2 (en) * 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
EP1309554A1 (fr) 2000-12-29 2003-05-14 Synthon Licensing, Ltd. Derive d'amide d'amlodipine
ES2254495T4 (es) 2000-12-29 2007-06-16 Pfizer Limited Hemimaleato de amlodipina.
SI1309555T1 (sl) * 2000-12-29 2005-12-31 Pfizer Ltd Postopek izdelave amlodipin-maleata
EP1346214A2 (fr) 2000-12-29 2003-09-24 Pfizer Limited Standards de reference destines a la determination de la purete ou de la stabilite de maleate d'amlodipine et procedes correspondants
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
EP1221438B1 (fr) * 2001-01-09 2007-03-14 Siegfried Generics International AG Sels d'amlodipine mésylate
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
US20030027848A1 (en) * 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
WO2003004025A1 (fr) * 2001-07-06 2003-01-16 Lek Pharmaceutical And Chemical Company D.D. Benzenesulfonate d'amlodipine de haute purete et procede de preparation correspondant
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
US6828339B2 (en) * 2001-11-21 2004-12-07 Synthon Bv Amlodipine salt forms and processes for preparing them
HU226642B1 (en) * 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
AU2003225370A1 (en) * 2002-04-13 2003-11-03 Hanlim Pharmaceutical Co., Ltd. Amlodipine nicotinate and process for the preparation thereof
ES2438008T3 (es) 2002-05-06 2014-01-15 Endocyte, Inc. Agentes de formación de imágenes dirigidos a vitaminas
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SI21233A (sl) * 2002-05-31 2003-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Kristalni hidratni obliki amlodipin benzensulfonata visoke čistote, postopki za njuno pripravo in uporaba
US6699892B2 (en) 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
RU2221784C1 (ru) * 2002-07-05 2004-01-20 Марвел Лайфсайнсез Прайвит Лимитед Способ получения бензолсульфоната амлодипина
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR100496436B1 (ko) 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR20040011751A (ko) * 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
PL374664A1 (en) 2002-08-29 2005-10-31 Taisho Pharmaceutical Co, Ltd. Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
US6784297B2 (en) * 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
CN100420673C (zh) * 2002-09-11 2008-09-24 韩林制药株式会社 S-(-)-氨氯地平烟酸盐及其制备方法
WO2004026834A1 (fr) * 2002-09-19 2004-04-01 Cj Corporation Sel acide organique cristallin d'amlodipine
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
EP1407773A1 (fr) * 2002-10-08 2004-04-14 Council of Scientific and Industrial Research Procede pour la preparation des sels de s(-)amlodipine
US20040072879A1 (en) * 2002-10-10 2004-04-15 Dr. Reddy's Laboratories Limited Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)
WO2004058711A1 (fr) * 2002-12-30 2004-07-15 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Isolation de derive de dihydropyridine et sels de preparation de celui-ci
EP1587792B1 (fr) 2003-01-27 2014-08-27 Hanmi Science Co., Ltd. Amlodipine camsylate stable et amorphe, procede de preparation associe et composition pour l'administration orale
JP3874419B2 (ja) * 2003-01-31 2007-01-31 三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
KR20040072363A (ko) * 2003-02-12 2004-08-18 주식회사 대웅 신규한 암로디핀 사이클라메이트 염 및 그의 제조방법
WO2004075825A2 (fr) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Formes posologiques d'amlodipine et leurs procedes de preparation
HRP20150056T1 (hr) 2003-04-25 2015-04-24 Cadila Healthcare Limited Soli clopidogrela i postupak pripreme
GB2415696B (en) * 2003-04-25 2007-06-20 Cipla Ltd Process for preparing amlodipine mesylate monohydrate
US20040248957A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
SG141430A1 (en) 2003-05-30 2008-04-28 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
RU2239433C1 (ru) * 2003-06-09 2004-11-10 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая вазодилатирующим, антиангинальным, гипотензивным и спазмолитическим действием, и способ ее изготовления
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
WO2005042485A1 (fr) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Sels d'addition acide d'amlodipine
KR100841409B1 (ko) * 2003-12-16 2008-06-25 에스케이케미칼주식회사 암로디핀 겐티세이트 염과 이의 제조방법
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030602A1 (en) * 2004-03-16 2006-02-09 Sepracor Inc. (S)-amlodipine malate
WO2005118166A2 (fr) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Composition pharmaceutique contenant de l'irbesartan
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
ES2339790T3 (es) * 2004-08-30 2010-05-25 Seo Hong Yoo Efecto neuroprotector de udca solubilizado en modelo isquemico focal.
DE602005027727D1 (de) * 2004-10-15 2011-06-09 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
EP1814558B1 (fr) * 2004-11-01 2010-12-15 Seo Hong Yoo Procedes et compositions de reduction de la neurodegeneration dans la sclerose laterale amyotrophique
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
WO2006059217A1 (fr) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Formes posologiques solides stables d'amlodipine bezylate, et procedes d'elaboration correspondants
WO2006070248A1 (fr) * 2004-12-28 2006-07-06 Ranbaxy Laboratories Limited Procedes permettant de preparer des formes posologiques pharmaceutiques solides et stables a base d'atorvastatine et d'amlodipine
US20080268049A1 (en) * 2005-02-11 2008-10-30 Dhaliwal Mona Stable Solid Dosage Forms of Amlodipine and Benazepril
JP5284779B2 (ja) * 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
WO2007001066A1 (fr) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Préparation pharmaceutique contenant un antagoniste du récepteur de l'angiotensine ii et un bloqueur du canal calcique
EP1930008A1 (fr) * 2005-09-28 2008-06-11 Teva Pharmaceutical Industries Ltd Composition stable d'hydrochlorure de benazepril
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
WO2008010223A2 (fr) 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugués de gaba anti-douleur
KR100795313B1 (ko) 2006-09-05 2008-01-21 현대약품 주식회사 암로디핀 베실레이트를 포함하는 약학 조성물
TWI399223B (zh) 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor
CN101167724B (zh) * 2006-10-25 2012-08-22 北京华安佛医药研究中心有限公司 含有氨氯地平的药物组合物在制备治疗下尿路疾病药物中的用途
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
CA2673336A1 (fr) * 2006-12-21 2008-06-26 Xenoport, Inc. Promedicaments diesters dimethyle substitues a base de levodopa et procedes d'utilisation
WO2008093984A1 (fr) 2007-01-29 2008-08-07 Hanall Pharmaceutical Company. Ltd Diamide acétate n, n- diméthyl imidodicarbonimidique, son procédé de production et compositions pharmaceutiques le comprenant
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US8748648B2 (en) 2007-09-06 2014-06-10 Nektar Therapeutics Oligomer-calcium channel blocker conjugates
US8143314B1 (en) * 2007-09-13 2012-03-27 Robert Carl Stover Methods and formulations for treating ineffective or decreased esophageal motility
JP5292404B2 (ja) * 2007-09-21 2013-09-18 ハンオル バイオファーマ カンパニー，リミテッド Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物
WO2009084003A1 (fr) 2007-12-31 2009-07-09 Lupin Limited Compositions pharmaceutiques d'amlodipine et de valsartan
US8207369B2 (en) 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
RU2359672C1 (ru) * 2008-02-18 2009-06-27 Зао "Биоком" Твердая лекарственная форма, предназначенная для лечения артериальной гипертензии и стенокардии, и способ ее получения
CN101564536B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物缓控释制剂
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9290445B2 (en) * 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US20110294860A1 (en) * 2008-12-17 2011-12-01 Medrx Co., Ltd. Aqueous oral preparation of stable amlodipine
SG173044A1 (en) 2009-01-23 2011-08-29 Hanmi Holdings Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
CA2789236C (fr) * 2009-11-09 2014-09-09 Xenoport, Inc. Compositions pharmaceutiques et formes galeniques orales d'un promedicament de levodopa et procedes d'utilisation
AU2010329440A1 (en) 2009-12-09 2012-08-09 Bar-Ilan University Methods of improving cognitive functions
ES2607806T5 (es) 2010-02-12 2024-10-07 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
WO2011104637A2 (fr) 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Formes cristallines du sel de trimésylate de perphénazine-gaba et procédé de production associé
WO2011117876A1 (fr) 2010-03-26 2011-09-29 Fdc Limited Procédé amélioré pour la préparation de base libre d'amlodipine et des sels d'addition d'acide de celle-ci
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EP2425859A1 (fr) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulations de l'olmesartane
PH12013500246A1 (en) * 2010-08-10 2019-10-11 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
BR112013010564B1 (pt) 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
EP2637502B1 (fr) 2010-11-10 2018-01-10 Celgene CAR LLC Inhibiteurs d'egfr sélectifs d'un mutant et leurs utilisations
WO2012071524A1 (fr) * 2010-11-24 2012-05-31 Ratiopharm Gmbh Sels d'arylsulfonates de fingolimod et leurs procédés de préparation
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
JP6317320B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の塩
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
CN105188371A (zh) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
US20150374713A1 (en) 2013-02-08 2015-12-31 Wockhardt Limited Stable pharmeceutical composition of amlodipine and benazepril or salts thereof
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016025561A1 (fr) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Formes et compositions d'un inhibiteur d'erk
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
CN104529877A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-癸酸离子液体及其制备方法和用途
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
CN104523588A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-硬脂酸离子液体及其制备方法和用途
EP3334466B1 (fr) 2015-08-14 2020-05-13 Endocyte, Inc. Méthode d'imagerie utilisant un composé chélateur
WO2017068532A1 (fr) 2015-10-23 2017-04-27 Ftf Pharma Private Limited Solution orale de dérivés de dihydropyridine
CN105395495A (zh) * 2015-11-30 2016-03-16 宜昌东阳光长江药业股份有限公司 一种含有苯磺酸氨氯地平的组合物及其制备方法
EP3219309A1 (fr) 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Compositions pharmaceutiques comprenant combinaisons à dose fixe de amlodipine, de candesartan cilexetil et de hydrochlorothiazide pour le traitement de l'hypertension
US20200316029A1 (en) 2016-05-30 2020-10-08 Boehringer Ingelheim International Gmbh Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
EP3960158B1 (fr) 2016-10-07 2025-05-21 Silvergate Pharmaceuticals, Inc. Formulations d'amlodipine
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP3501502A1 (fr) 2017-12-20 2019-06-26 Midas Pharma GmbH Compositions pharmaceutiques dosées fixes comprenant de l'amlodipine, du ramipril et de l'atorvastatine
WO2019200143A1 (fr) 2018-04-11 2019-10-17 Silvergate Pharmaceuticals, Inc. Formulations d'amlodipine
CN112955965B (zh) 2018-06-14 2024-04-09 阿斯利康(英国)有限公司 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法
WO2020150473A2 (fr) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Inhibiteurs de pcsk9 et leurs procédés d'utilisation
US11253474B1 (en) 2021-02-01 2022-02-22 Liqmeds Worldwide Limited Pharmaceutical solution of amlodipine
EP4052695A1 (fr) 2021-03-05 2022-09-07 Midas Pharma GmbH Compositions pharmaceutiques orales stables à libération immédiate à dose fixe comprenant de l'amlodipine, de l'atorvastatine et du candésartan cilexétil
EP4370101A1 (fr) 2021-07-15 2024-05-22 Adamed Pharma S.A. Composition pharmaceutique comprenant de l'amlodipine, du candésartan cilexetil et de l'hydrochlorothiazide pour le traitement de l'hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816612A (en) * 1967-03-23 1974-06-11 Degussa Process for the production of basically reacting pharmaceuticals
US4032637A (en) * 1972-09-26 1977-06-28 Sandoz Ltd. Method of promoting sleep
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
JPS5547656A (en) * 1978-09-29 1980-04-04 Dainippon Pharmaceut Co Ltd 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative
CS228917B2 (en) * 1981-03-14 1984-05-14 Pfizer Method of preparing substituted derivatives of 1,4-dihydropyridine
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
ZA839187B (en) * 1982-12-10 1984-07-25 Ciba Geigy Ag Amide compounds

Also Published As

Publication number Publication date
SK278435B6 (en) 1997-05-07
DK171708B1 (da) 1997-04-01
GR870525B (en) 1987-08-12
NO871408L (no) 1987-10-05
FR2596758B1 (fr) 1988-12-02
CS353991A3 (en) 1992-04-15
SG59692G (en) 1992-12-04
CZ289095B6 (cs) 2001-10-17
AP50A (en) 1989-09-16
MX5847A (es) 1993-08-01
SE463457B (sv) 1990-11-26
FI871470L (fi) 1987-10-05
FI85017C (fi) 1992-02-25
CS265237B2 (en) 1989-10-13
DE3710457A1 (de) 1987-10-08
NO871408D0 (no) 1987-04-03
GB8707653D0 (en) 1987-05-07
KR950006710B1 (ko) 1995-06-21
IE870869L (en) 1987-10-04
AR242562A1 (es) 1993-04-30
AU573123B2 (en) 1988-05-26
EP0244944A3 (en) 1988-01-07
EP0244944A2 (fr) 1987-11-11
YU44801B (en) 1991-02-28
ES2012803B3 (es) 1990-04-16
IT8719977A0 (it) 1987-04-03
GB8608335D0 (en) 1986-05-08
SE8701348L (sv) 1987-10-05
HUT43821A (en) 1987-12-28
US4879303A (en) 1989-11-07
IL82101A (en) 1991-01-31
FI85017B (fi) 1991-11-15
ZA872439B (en) 1988-11-30
JPH037668B2 (fr) 1991-02-04
UA6344A1 (uk) 1994-12-29
SE8701348D0 (sv) 1987-03-31
MY101177A (en) 1991-07-31
CN87102493A (zh) 1987-10-14
JPS62240660A (ja) 1987-10-21
FR2596758A1 (fr) 1987-10-09
IT1203853B (it) 1989-02-23
DE3761485D1 (de) 1990-03-01
BE1000130A4 (fr) 1988-04-12
NZ219868A (en) 1989-02-24
IE59457B1 (en) 1994-02-23
NO172181B (no) 1993-03-08
FI871470A0 (fi) 1987-04-03
CA1321393C (fr) 1993-08-17
IL82101A0 (en) 1987-10-30
NO172181C (no) 1993-06-16
GR3000394T3 (en) 1991-06-07
CN1023800C (zh) 1994-02-16
HK76092A (en) 1992-10-09
AP8700060A0 (en) 1987-02-01
YU58087A (en) 1988-08-31
BG60698B2 (en) 1995-12-29
LU86812A1 (fr) 1987-08-12
PT84611B (pt) 1989-11-30
NL8700791A (nl) 1987-11-02
PL264982A1 (en) 1988-05-26
SU1498388A3 (ru) 1989-07-30
DK170187A (da) 1987-10-05
ES2002599A6 (es) 1988-08-16
DK170187D0 (da) 1987-04-03
DD265142A5 (de) 1989-02-22
EG18266A (en) 1992-12-30
ECSP941129A (es) 1994-12-15
PH24348A (en) 1990-06-13
EP0244944B1 (fr) 1990-01-24
GB2188630B (en) 1990-04-04
ATE49752T1 (de) 1990-02-15
KR870009998A (ko) 1987-11-30
AU7103087A (en) 1987-10-08
CY1669A (en) 1993-05-14
CS236387A2 (en) 1989-01-12
IN168414B (fr) 1991-03-30
PT84611A (en) 1987-05-01
HU196962B (en) 1989-02-28
PL149532B1 (en) 1990-02-28
GB2188630A (en) 1987-10-07

Similar Documents

Publication Publication Date Title
FI871492L (fi) Menetelmä lääkeaineina käyttökelpoisten 2-tiometyyli-substituoitujen 1,4-dihydropyridiinien valmistamiseksi
PT84237A (en) Process for preparing neurite-promoting factor
FR2621785B1 (fr) Procede de preparation d'un roux
FI873350A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,4-dihydropyridiinijohdannaisten valmistamiseksi
EP0234776A3 (en) Process for 1,4-dihydropyridine compounds
PT80956A (en) Process for preparing 1,4-dihydropyridines
YU201987A (en) Process for obtaining dihydropyridine
PT84959A (en) Process for the preparation of novel 1,4-dihydropyridines
HUT45499A (en) Process for producing optically active 1,4-dihydropyridine derivatives
FR2599369B1 (fr) Procede de preparation de disilylmethanes
MA21130A1 (fr) Procede de preparation de nouveaux aminopropionamides .
FR2609027B1 (fr) Procede de preparation de mercaptoalcools
FR2607808B1 (fr) Procede de preparation de trifluoromethylbenzonitrile a partir de trifluoromethylbenzaldehyde
FI891111A7 (fi) Menetelmä 1,4-dihydropyridiinijohdannaisten valmistamiseksi
GB8824278D0 (en) New isopolypeptides & process for preparation thereof
DE3760307D1 (en) Process for the preparation of 1,1,2-trialkoxyethane
DK0377437T3 (da) Fremgangsmåde til fremstilling af 2,4-diamino-6-piperidinylpyrimidin-3-N-oxid
FR2605318B1 (fr) Procede de preparation d'azetidinones.
FR2604703B1 (fr) Procede de preparation de polyfluoroenolates
GB2185035B (en) Process for preparing 1,4-diaminoanthraquinone-2,3-disubstituted compound
FR2602764B1 (fr) Composes dichlorotrifluoromethyltoluenes et procede de preparation de ces composes
PT85185A (en) Process for the preparation of 3,7-dihydro-3-n-propyl-1h-purine-2,6-dione
FR2632303B1 (fr) Procede de preparation du 3-aminocrotonate de methyle
FR2595353B1 (fr) Procede de preparation d'encainide
FR2597863B1 (fr) Procede de preparation d'aldehydes aromatiques